Literature DB >> 11327878

The first epidermal growth factor-like domain of the low-density lipoprotein receptor contains a noncanonical calcium binding site.

S Malby1, R Pickering, S Saha, R Smallridge, S Linse, A K Downing.   

Abstract

Removal of cholesterol-containing particles from the circulation is mediated by the low-density lipoprotein (LDL) receptor. Upon ligand binding, the receptor-ligand complex is endocytosed, and the ligand is released. The important biological role of the LDL receptor (LDLR) has been highlighted by the identification of more than 400 LDLR mutations that are associated with familial hypercholesterolemia. The extracellular region of the LDLR is modular in nature and principally comprises multiple copies of ligand binding, epidermal growth factor-like (EGF), and YWTD-type domains. This report describes characterization of the calcium binding properties of the tandem pair of EGF domains. While only the C-terminal EGF module contains the consensus sequence associated with calcium binding, a noncanonical calcium binding site in the N-terminal domain has been revealed using solution NMR spectroscopy. The calcium dissociation constants for the N- and C-terminal sites have been measured under physiologically relevant pH and ionic strength conditions using a combination of solution NMR, intrinsic protein fluorescence, and chromophoric chelator methods to be approximately 50 microM and approximately 10-20 microM, respectively. Identification of the novel calcium binding motif in LDLR sequences from other species suggests that it may confer specificity within the LDLR gene family. Comparison of the K(d) for the C-terminal site with the calcium concentration in late vesicles indicates that the binding properties of this module may be tuned to titrate upon endocytosis of the LDL receptor-ligand complex, and thus calcium binding may play a role in the ligand dissociation process.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11327878     DOI: 10.1021/bi002322l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Binding of calcium to anticoagulant protein S: role of the fourth EGF module.

Authors:  Kristina E M Persson; Johan Stenflo; Sara Linse; Yvonne Stenberg; Roger J S Preston; David A Lane; Suely M Rezende
Journal:  Biochemistry       Date:  2006-09-05       Impact factor: 3.162

Review 2.  How multi-scale structural biology elucidated context-dependent variability in ectodomain conformation along with the ligand capture and release cycle for LDLR family members.

Authors:  Terukazu Nogi
Journal:  Biophys Rev       Date:  2017-12-04

3.  Calcium as a crucial cofactor for low density lipoprotein receptor folding in the endoplasmic reticulum.

Authors:  Florentina Pena; Annemieke Jansens; Guus van Zadelhoff; Ineke Braakman
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

Review 4.  The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.

Authors:  Steve Poirier; Gaétan Mayer
Journal:  Drug Des Devel Ther       Date:  2013-10-04       Impact factor: 4.162

5.  Structural basis for ligand capture and release by the endocytic receptor ApoER2.

Authors:  Hidenori Hirai; Norihisa Yasui; Keitaro Yamashita; Sanae Tabata; Masaki Yamamoto; Junichi Takagi; Terukazu Nogi
Journal:  EMBO Rep       Date:  2017-04-26       Impact factor: 8.807

6.  Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.

Authors:  Michael T Lipari; Wei Li; Paul Moran; Monica Kong-Beltran; Tao Sai; Joyce Lai; S Jack Lin; Ganesh Kolumam; Jose Zavala-Solorio; Anita Izrael-Tomasevic; David Arnott; Jianyong Wang; Andrew S Peterson; Daniel Kirchhofer
Journal:  J Biol Chem       Date:  2012-11-07       Impact factor: 5.157

7.  Ca2+ binding to complement-type repeat domains 5 and 6 from the low-density lipoprotein receptor-related protein.

Authors:  Olav M Andersen; Henrik Vorum; Bent Honoré; Hans C Thøgersen
Journal:  BMC Biochem       Date:  2003-08-18       Impact factor: 4.059

Review 8.  Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.

Authors:  Nicola Ferri
Journal:  Scientifica (Cairo)       Date:  2012-09-11

9.  Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts.

Authors:  My-Anh Nguyen; Tanja Kosenko; Thomas A Lagace
Journal:  J Lipid Res       Date:  2013-12-02       Impact factor: 5.922

Review 10.  PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs.

Authors:  Nikolay Kuzmich; Elena Andresyuk; Yuri Porozov; Vadim Tarasov; Mikhail Samsonov; Nina Preferanskaya; Valery Veselov; Renad Alyautdin
Journal:  Molecules       Date:  2022-01-10       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.